Definitive Healthcare Corp
For the period ended Jun 30, 2024. Filed Aug 5, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 5, 2024
What changed in Risk Factors?
Read the current filingPrevious report: 10-Q
Period ended 2024-03-31; filed 2024-05-07.
0000950170-24-054539
Item 1A. Risk FactorsUnregistered Sales of Equity Securities and Use of ProceedsDefaults Upon Senior SecuritiesMine Safety DisclosuresOther InformationCurrent report: 10-Q
Period ended 2024-06-30; filed 2024-08-05.
0000950170-24-090808
Item 1A. Risk FactorsUnregistered Sales of Equity Securities and Use of ProceedsDefaults Upon Senior SecuritiesMine Safety DisclosuresOther InformationThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 13 previous paragraphs and 13 current paragraphs.
11 unchanged; 0 reworded; 2 added; 2 removed; 0 previous and 0 current paragraphs rearranged.
Tables are not compared: 1 previous and 2 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
The current filing states there were no material changes to risk factors.
This is the filer’s own statement, not a conclusion from the comparison. Read its qualifications and the report it references.
Current filing’s statement
For a more detailed discussion of our risks and uncertainties, see also Item 1A – Risk Factors in our 2023 Form 10-K. There have been no material changes in our risk factors since the filing of our 2023 Form 10-K.
Added paragraphs (2)
Current report
The following table sets forth certain information with respect to repurchases of our Class A Common Stock during the quarter ended June 30, 2024.
Current report
On May 7, 2024, our Board of Directors announced a stock repurchase program (the “Repurchase Program”) of our Class A Common Stock authorizing up to $20.0 million in share repurchases. The Repurchase Program expires on December 31, 2024. Repurchases may be effected, from time to time, either on the open market (including pre-set trading plans), in privately negotiated transactions, and other transactions in accordance with applicable securities laws.
Removed paragraphs (2)
Previous report
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Previous report
On May 1, 2024, as part of its planning and organizational design with respect to its executive leadership team, the Company agreed with Jonathan Maack that the President position that he held would be eliminated. Accordingly, Mr. Maack will remain employed with the Company through May 31, 2024. Mr. Maack’s departure constitutes a termination of employment without “cause” for purposes of any employment, equity compensation, or benefit agreement, plan, or arrangement of the Company and its subsidiaries to which Mr. Maack is a party or otherwise participates. In addition, effective May 1, 2024, Kate Shamsuddin Jensen was appointed as the Company’s Chief Strategy Officer, transitioning from her prior role of Chief Product Officer.